Merck Elects Paul Diaz, Ex-CEO Of Myriad Genetics And Kindred Healthcare, To 14-Member Board
Diaz joins November 1 and will sit on the Audit and Research committees, with a shareholder vote due in May 2027.
Merck elected Paul J. Diaz, a managing partner at Cressey & Company, to its board effective November 1, 2026, according to an 8-K filed Tuesday. His arrival brings the board to 14 members.
What the filing says
The board put Diaz on two committees: Audit and Research. He will stand for election by shareholders in May 2027, the company said in a press release attached to the filing.
He will be paid as a non-employee director under the practices described in the "Director Compensation" section of Merck's proxy statement filed April 8, 2026. The 8-K says he has no arrangement with anyone else tied to his election, and no related-party relationship with Merck that requires disclosure.
Chairman and CEO Rob Davis said in the release: "Paul brings extensive leadership and business expertise in the healthcare industry, and we look forward to his contributions and insights."
Who Diaz is
Cressey & Company, where Diaz is a managing partner, is a private investment firm focused on health care companies. He previously served as president and CEO of Myriad Genetics, a genetic testing and precision medicine company. Before that he held the same roles at Kindred Healthcare, a healthcare services company.
He also serves on the board of Centene, the Board of Trustees of Johns Hopkins Medicine and the Board of Visitors of the Georgetown University Law Center. He holds a bachelor's degree in finance and accounting from American University and a J.D. from Georgetown University.
In Tuesday trading, as of 12:46 p.m. ET, Merck shares were at $143.12, down 1.60% from the prior close of $145.45. The filing links no cause to that move.
What to watch
Diaz's seat begins November 1. His first test with shareholders is the May 2027 election.
The filing sets two dates for Diaz: November 1 for his seat and May 2027 for the vote.